NEWS RELEASE

Teijin Pharma and TransThera Biosciences Form
Strategic R&D Collaboration
Tokyo, Japan, and Nanjing, China, December 18, 2020 -- Teijin Pharma Limited (“TeijinPharma”), the core company of the Teijin Group’s healthcare business headquartered inTokyo, Japan, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage
biotechnology company based in Nanjing, China, jointly announced that they have enteredinto a strategic collaboration agreement for joint research and development of the innovative
drugs in the target fields of oncology and inflammatory diseases.
Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple
drug targets with the immediate goal of acquiring compounds as candidates for new drug
development based on the targets and compounds found by Teijin Pharma, and share theresearch outcomes in both Japan and China. Also, the two companies will share a global
development license when the compound enters the development stage and consider the joint
development and launch of new drugs in Japan, China, and rest of the world.
Teijin Pharma and TransThera have the same vision in prompt supply of innovative new drugsto patients with unmet medical needs around the world. The two companies are confident thatthey can complement the strengths of their research foundations for small molecule drug
discovery in a manner of time and cost saving and accuracy enhancement in new drug
development.
“We are delighted to create innovative new drugs together with TransThera,” said Ichiro
Watanabe, president of Teijin Pharma Limited. “Under the Teijin Group’s current medium-term
management plan, we are contributing to sustainability by developing solutions for ademographic change and increased health consciousness. Launching new drugs will be akey factor in our implementation of this plan and we look forward to creating innovative new
drugs together with TransThera.”“I am very excited about the opportunity for TransThera to work with Teijin pharma, a leading
R&D based company of high repute with admirable tradition,” said Frank Wu, CEO ofTransThera. “Combining both companies’ outstanding target validation expertise, lead
identification capability and development platform will certainly expedite the drug discovery
process, hopefully bringing more drug therapies to the patients. I look forward to theproductive work ahead.”“I believe that this collaboration between Japanese and Chinese companies with a proactive
mindset would set a new R&D model to increase R&D productivity and manage R&D risk,”
Keiji Kawamoto, Senior Advisor of External Alliance of TransThera and co-founder of KoMong

& Associates added. “I am pleased that my KoMong team members contribute significantly
toward this exciting collaboration.”
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fieldsof environmental value; safety, security and disaster mitigation; and demographic change andincreased health consciousness. Originally established as Japan's first rayon manufacturer in
1918, Teijin has evolved into a unique enterprise encompassing three core business domains:high-performance materials including aramid, carbon fibers and composites, and also resinand plastic processing, films, polyester fibers and products converting; healthcare including
pharmaceuticals and home healthcare equipment for bone/joint, respiratory andcardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT
including B2B solutions for medical, corporate and public systems as well as packaged
software and B2C online services for digital entertainment. Deeply committed to its
stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions”,
Teijin aims to be a company that supports the society of the future. The group comprises morethan 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin
posted consolidated sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2020.
About TransThera Biosciences
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing
innovative therapeutics to target diseases with major unmet medical needs via internal
research platform and open innovation. TransThera's current portfolio covers therapeuticareas such as oncology, cardiovascular, and inflammatory diseases. For more information,please visit www.transtherabio.com.
About KoMong & Associates
KoMong & Associates was founded in Tokyo, Japan by Dr. Yasushi Honma, Mr. Hidehiro Ando, and Mr. Keiji Kawamoto to realize pharma’s innovative growth through “China-Japan CrossBorder Collaboration”. KoMong & Associates promotes collaborations with Japanese com
panies as the consultancy function of TransThera.
Please visit https://transtherabio.jp/partners.html

Press Contact
Teijin Limited
Corporate Communications
pr@teijin.co.jp